Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Vγ9Vδ2 T Cells for Malignant Glioma
NCT06396481Phase 1Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Vγ9Vδ2 T cells in malignant glioma, sponsored by Beijing Tiantan Hospital. Primary endpoint: Safety evaluation at 12 months. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
Vγ9Vδ2 T cells
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT06396481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396481.